Astaxanthin supplementation is associated with a reduction in serum myeloperoxidase levels in subjects with abdominal obesity
Open Access
- 11 August 2026
- journal article
- Published by Pensoft Publishers in Pharmacia
- Vol. 73, e200901
Abstract
Background : Central obesity is a condition characterized by increased abdominal adipose tissue and an increased risk of developing cardiometabolic diseases. In subjects with obesity, elevated myeloperoxidase (MPO) levels are observed because of the infiltration of polymorphonuclear leukocytes into adipose tissue, leading to increased oxidative stress. This study aimed to assess the effect of astaxanthin supplementation, a compound with strong antioxidant properties, on serum MPO levels in adult subjects with central obesity. Methods : This study is a quasi-experimental study with an open-label, prospective design. A total of 42 subjects with abdominal obesity participated in the study, including 21 subjects who received 4 mg of astaxanthin supplementation per day for 4 weeks and 21 control subjects who did not receive supplementation. Serum MPO levels were measured using an enzyme-linked immunosorbent assay (ELISA) before and after the intervention. Results : There was a significant difference in MPO levels before and after treatment among subjects with central obesity who received astaxanthin (median 20.30 [16.16] vs. 17.29 [10.23] pg/mL; p = 0.014), whereas there was no difference in MPO levels before and after the study period among subjects in the control group (median 19.94 [7.17] vs. 17.49 [9.14] pg/mL; p = 0.876). Conclusion : Supplementation with 4 mg of astaxanthin for 4 weeks reduces serum MPO levels in adult subjects with central obesity.Keywords
This publication has 11 references indexed in Scilit:
- The Role of Astaxanthin as an Antioxidant and Anti-Inflammatory Agent in Human Health: A Systematic ReviewInternational Journal of Molecular Sciences, 2026
- Correlation Analysis of Galectin-3 Serum Level in Obesity with and without ObesityINDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY, 2023
- The Role of Astaxanthin as a Nutraceutical in Health and Age-Related ConditionsMolecules, 2022
- Role of myeloperoxidase in inflammation and atherosclerosis (Review)Biomedical Reports, 2022
- Effect of obesity, glucose control, lipid profiles, and blood pressure on Lp-PLA2 levels in type 2 diabetes mellitus patientsObesity Medicine, 2021
- Astaxanthin Inhibits Helicobacter pylori-induced Inflammatory and Oncogenic Responses in Gastric Mucosal Tissues of MiceJournal of Cancer Prevention, 2020
- Investigating the Role of Myeloperoxidase and Angiopoietin-like Protein 6 in Obesity and DiabetesScientific Reports, 2020
- Myeloperoxidase as an Active Disease Biomarker: Recent Biochemical and Pathological PerspectivesMedical Sciences, 2018
- Obesity, Oxidative Stress, Adipose Tissue Dysfunction, and the Associated Health Risks: Causes and Therapeutic StrategiesMetabolic Syndrome and Related Disorders, 2015
- Myeloperoxidase Is Associated with Insulin Resistance and Inflammation in Overweight Subjects with First-Degree Relatives with Type 2 Diabetes MellitusDiabetes & Metabolism Journal, 2015